Warfarin-Rifampin-Gene (WARIF-G) Interaction: A Retrospective, Genetic, Case-Control Study.
Journal
Clinical pharmacology and therapeutics
ISSN: 1532-6535
Titre abrégé: Clin Pharmacol Ther
Pays: United States
ID NLM: 0372741
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
received:
15
12
2022
accepted:
05
02
2023
medline:
19
4
2023
pubmed:
16
2
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Warfarin is extensively metabolized by cytochrome P450 2C9 (CYP2C9). Concomitant use with the potent CYP2C9 inducer, rifampin, requires close monitoring and dosage adjustments. Although, in theory, warfarin dose increase should overcome this interaction, most reported cases over the last 50 years have not responded even to high warfarin doses, but some have responded to modest doses. To investigate the genetic polymorphisms' impact on this unexplained interpatient variability, we performed genotyping of CYP2C9, VKORC1, and CYP4F2 for warfarin and rifampin concomitant receivers from 2016 to 2022 at Hamad Medical Corporation, Doha, Qatar. We identified and included 36 patients: 22 responders and 14 nonresponders. Warfarin-responders were significantly more likely to have one or more warfarin-sensitizing CYP2C9/VKORC1 alleles than nonresponders (odds ratio = 23.2, 95% confidence interval = 3.2-195.6; P = 0.0001). The mean genetic-based pre-interaction calculated dose was significantly lower for responders than for nonresponders (P < 0.001); and was negatively correlated with warfarin sensitivity index (WSI) (r = -0.58; P = 0.0002). The median percentage time in therapeutic range and mean WSI were significantly higher in the warfarin-sensitizing CYP2C9/VKORC1 alleles carriers than noncarriers (P = 0.017 and 0.0004, respectively). Whereas the warfarin-sensitizing CYP2C9/VKORC1 genotypes were associated with modest on-rifampin warfarin dose requirements, the noncarriers would have required more than double these doses to respond. Warfarin-sensitizing CYP2C9/VKORC1 genotypes and low genetic-based warfarin calculated doses were associated with higher warfarin sensitivity and better anticoagulation quality in patients receiving rifampin concomitantly.
Substances chimiques
Warfarin
5Q7ZVV76EI
Anticoagulants
0
Cytochrome P-450 CYP2C9
EC 1.14.13.-
Rifampin
VJT6J7R4TR
Aryl Hydrocarbon Hydroxylases
EC 1.14.14.1
Vitamin K Epoxide Reductases
EC 1.17.4.4
VKORC1 protein, human
EC 1.17.4.4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1150-1159Informations de copyright
© 2023 The Authors. Clinical Pharmacology & Therapeutics © 2023 American Society for Clinical Pharmacology and Therapeutics.
Références
Perreault, S. et al. Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation. Pharmacotherapy 40, 40-54 (2020).
January, C.T. et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines and the Heart Rhythm Society. J. Am. Coll. Cardiol. 74, 104-132 (2019).
Stevens, S.M. et al. Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest 160, e545-e608 (2021).
Ageno, W., Beyer-Westendorf, J., Garcia, D.A., Lazo-Langner, A., McBane, R.D. & Paciaroni, M. Guidance for the management of venous thrombosis in unusual sites. J. Thromb. Thrombolysis 41, 129-143 (2016).
Johnson, J.A. et al. Clinical pharmacogenetics implementation consortium (CPIC) guideline for pharmacogenetics-guided warfarin dosing: 2017 update. Clin. Pharmacol. Ther. 102, 397-404 (2017).
Fahmi, A.M., Mohamed, A., Elewa, H. & Saad, M.O. Preemptive dose adjustment effect on the quality of anticoagulation management in warfarin patients with drug interactions: a retrospective cohort study. Clin. Appl. Thromb. Hemost. 25, 1-6 (2019).
Colling, M.E., Tourdot, B.E. & Kanthi, Y. Inflammation, infection and venous thromboembolism. Circ. Res. 128, 2017-2036 (2021).
Danwang, C., Bigna, J.J., Awana, A.P., Nzalie, R.N. & Robert, A. Global epidemiology of venous thromboembolism in people with active tuberculosis: a systematic review and meta-analysis. J. Thromb. Thrombolysis 51, 502-512 (2021).
Habib, G. et al. ESC guidelines for the management of infective endocarditis: the task force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur. Heart J. 36, 3075-3128 (2015).
Migliori, G.B. et al. Clinical standards for the diagnosis, treatment and prevention of TB infection. Int. J. Tuberc. Lung Dis. 26, 190-205 (2022).
Foerster, K.I., Hermann, S., Mikus, G. & Haefeli, W.E. Drug-drug interactions with direct oral anticoagulants. Clin. Pharmacokinet. 59, 967-980 (2020).
MacDougall, C., Canonica, T., Keh, C., Phan, B.A. & Louie, J. Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management. Pharmacotherapy 42, 343-361 (2022).
U.S. Food and Drug Administration. Drug development and drug interactions: table of substrates, inhibitors and inducers <https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers> (2020). Accessed March 26, 2022.
Hudson (OH): Lexicomp Inc. <http://www.lexicomp.com> (2022). Accessed March 26, 2022.
Wiggins, B.S., Dixon, D.L., Neyens, R.R., Page, R.L. & Gluckman, T.J. Select drug-drug interactions with direct oral anticoagulants: JACC review topic of the week. J. Am. Coll. Cardiol. 75, 1341-1350 (2020).
Chen, Y., Ferguson, S.S., Negishi, M. & Goldstein, J.A. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther. 308, 495-501 (2004).
O'Reilly, R.A. Interaction of sodium warfarin and rifampin. Studies in man. Ann. Intern. Med. 81, 337-340 (1974).
O'Reilly, R.A. Interaction of chronic daily warfarin therapy and rifampin. Ann. Intern. Med. 83, 506-508 (1975).
Heimark, L.D., Gibaldi, M., Trager, W.F., O'Reilly, R.A. & Goulart, D.A. The mechanism of the warfarin-rifampin drug interaction in humans. Clin. Pharmacol. Ther. 42, 388-394 (1987).
Romankiewicz, J.A. & Ehrman, M. Rifampin and warfarin: a drug interaction. Ann. Intern. Med. 82, 224-225 (1975).
Self, T.H. & Mann, R.B. Interaction of rifampin and warfarin. Chest 67, 490-491 (1975).
Almog, S., Martinowitz, U., Halkin, H., Bank, H.Z. & Farfel, Z. Complex interaction of rifampin and warfarin. South. Med. J. 81, 1304-1306 (1988).
Poller, L. International normalized ratios (INR): the first 20 years. J. Thromb. Haemost. 2, 849-860 (2004).
Casner, P.R. Inability to attain oral anticoagulation: warfarin-rifampin interaction revisited. South. Med. J. 89, 1200-1203 (1996).
Lee, C.R. & Thrasher, K.A. Difficulties in anticoagulation management during coadministration of warfarin and rifampin. Pharmacotherapy 21, 1240-1246 (2001).
Kim, K.Y., Epplen, K., Foruhari, F. & Alexandropoulos, H. Update on the interaction of rifampin and warfarin. Prog. Cardiovasc. Nurs. 22, 97-100 (2007).
Krajewski, K.C. Inability to achieve a therapeutic INR value while on concurrent warfarin and rifampin. J. Clin. Pharmacol. 50, 710-713 (2010).
Maina, M.W., Pastakia, S.D., Manji, I., Kirui, N., Kirwa, C. & Karwa, R. Describing the profile of patients on concurrent rifampin and warfarin therapy in western Kenya: a case series. Drugs. R. D. 13, 191-197 (2013).
Fahmi, A.M., Abdelsamad, O. & Elewa, H. Rifampin-warfarin interaction in a mitral valve replacement patient receiving rifampin for infective endocarditis: a case report. Springerplus 5, 8 (2016).
Shibata, S. et al. Delayed de-induction of CYP2C9 compared to CYP3A after discontinuation of rifampicin: report of two cases. Int. J. Clin. Pharmacol. Ther. 55, 449-452 (2017).
Martins, M.A. et al. Rifampicin-warfarin interaction leading to macroscopic hematuria: a case report and review of the literature. BMC Pharmacol. Toxicol. 14, 27 (2013).
Yang, C.S., Boswell, R. & Bungard, T.J. A case series of the rifampin-warfarin drug interaction: focus on practical warfarin management. Eur. J. Clin. Pharmacol. 77, 341-348 (2021).
Raru, Y., Abouzid, M., Zeid, F. & Teka, S. Pulmonary vein thrombosis secondary to tuberculosis in a non-HIV infected patient. Respir. Med. Case. Rep. 26, 91-93 (2018).
Salem, M., Eljilany, I., El-Bardissy, A. & Elewa, H. Genetic polymorphism effect on warfarin-rifampin interaction: a case report and review of literature. Pharmgenomics. Pers. Med. 14, 149-156 (2021).
Daly, A.K., Rettie, A.E., Fowler, D.M. & Miners, J.O. Pharmacogenomics of CYP2C9: functional and clinical considerations. J. Pers. Med. 8, 1 (2017).
Teva Pharmaceuticals USA, Inc. (warfarin sodium) tablet. 2007 [rev. 2021 Aug] DailyMed [Internet]. Bethesda (MD): National Library of Medicine (US). <https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=0cbce382-9c88-4f58-ae0f-532a841e8f95&type=pdf> (2020). Accessed September 26, 2022.
Fahmi, A.M., Elewa, H. & El Jilany, I. Warfarin dosing strategies evolution and its progress in the era of precision medicine, a narrative review. Int. J. Clin. Pharmacol. 44, 599-607 (2022).
Shah, R.R. & Smith, R.L. Addressing phenoconversion: the Achilles' heel of personalized medicine. Br. J. Clin. Pharmacol. 79, 222-240 (2015).
Klomp, S.D., Manson, M.L., Guchelaar, H.J. & Swen, J.J. Phenoconversion of cytochrome P450 metabolism: a systematic review. J. Clin. Med. 9, 2890 (2020).
Vormfelde, S.V. et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin. Pharmacol. Ther. 86, 54-61 (2009).
George, M., Shewade, D.G., Kumar, S.V. & Adithan, C. Effect of anti-tuberculosis therapy on polymorphic drug metabolizing enzyme CYP2C9 using phenytoin as a probe drug. Indian J. Pharm. 44, 485-488 (2012).
Genotek D. Laboratory protocol for manual purification of DNA from 0.5 mL of sample. <http://www.dnagenotek.com/US/pdf/PD-PR-006.pdf> (2018).
Rosendaal, F.R., Cannegieter, S.C., van der Meer, F.J. & Briët, E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb. Haemost. 69, 236-239 (1993).
Sridharan, K. et al. Influence of CYP2C9, VKORC1, and CYP4F2 polymorphisms on the pharmacodynamic parameters of warfarin: a cross-sectional study. Pharmacol. Rep. 73, 1405-1417 (2021).
Takase, T. et al. Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. J. Pharm. Health. Care. Sci. 4, 13 (2018).
Agrawal, S. et al. Impact of CYP2C9-interacting drugs on warfarin pharmacogenomics. Clin. Transl. Sci. 13, 941-949 (2020).
Cheng, S., Flora, D.R., Rettie, A.E., Brundage, R.C. & Tracy, T.S. Pharmacokinetic modeling of warfarin I - model-based analysis of warfarin enantiomers with a target mediated drug disposition model reveals CYP2C9 genotype-dependent drug-drug interactions of S-warfarin. Drug Metab. Dispos. 50, 1287-1301 (2022).
Imai, H., Kotegawa, T. & Ohashi, K. Duration of drug interactions: putative time courses after mechanism-based inhibition or induction of CYPs. Expert. Rev. Clin. Pharmacol. 4, 409-411 (2011).
Yang, J. et al. Cytochrome P450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions. Curr. Drug Metab. 9, 384-394 (2008).